A prognostic model for the development of post-laser hyperpigmentation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008763

Enrollment

Registered

2023-09-01

Start date

2022-04-28

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Treatment group: Melanon cream (hydroquinone 50mg/g, tretinoin 0.03mg/g and hydrocortisone 10mg/g), once daily after emollient use, apply on skin Control group: emollient only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged over or equal to 19 years 2. have at least one solar lentigo

Exclusion criteria

Exclusion criteria: if they were treated for the solar lentigo; had undergone any energy-based procedures involving solar lentigo lesions in the previous 12 months; were immunosuppressed or treated with immunosuppressive agents in the previous 4 weeks; had used topical steroid, retinoid, hydroquinone, or any depigmenting agents in the previous 12 weeks; had a history of keloid; had diabetes mellitus or any condition that could affect would healing; had infection or other skin disease in the solar lentigo lesion; or had photosensitivity or taking photosensitive medications.

Design outcomes

Primary

Measure	Time frame
The number of postinflammatory hyperpigmentation	—

Secondary

Measure	Time frame
Average melanin	—

Countries

Korea, Republic of

Contacts

Public ContactSoon-Hyo Kwon

Kyung Hee University Hospital at Gangdong

soonhyo17@hanmail.net+82-2-440-7329

Outcome results